Hendrik Bonnemeier

Hendrik Bonnemeier

Auto-generated profile, based on publicly available information

Hendrik Bonnemeier

Institute of life science University of Applied Sciences Bremerhaven 27568 Bremerhaven Germany

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 October 2023 in EP Europace
Verified
Journal Article
Open access
PDF file
SBStefan Borov
Stefan Borov
BBBenito Baldauf
Benito Baldauf
JHJana Henke
Jana Henke
HPHerribert Pavaci
Herribert Pavaci
APArben Perani
Arben Perani
HBHendrik Bonnemeier
Hendrik Bonnemeier
TauroPace (Tauropharm, Bavaria Germany), a taurolidine solution for combating cardiac implantable electronic device (CIED) infection, was compared with a historical control of 3% hydrogen peroxide (H2O2) in a prospective observational study. The device pocket was irrigated, and all hardware accessible within (leads, suture sleeves, pulse generator) was wiped with H2O2, TauroPace, or taurolidine in a galenic formulation during any invasive CIED procedure at the study centre. Only CIED procedures covered by TauroPace or H2O2 from 1 January 2017 to 28 February 2022 were included for analysis. Patients who underwent >1 procedure were censored for the last treatment group and reassigned at the next procedure. The primary endpoint was major CIED infection within 3 months. The secondary endpoints were CIED infection beyond 3 months, adverse events potentially related to the antimicrobial solutions, CIED system, procedure, and death, till the end of follow-up. TauroPace covered 654 procedures on 631 patients, and H2O2 covered 551 procedures on 532 patients. The TauroPace group had more patient risk factors for infection than the H2O2 group (P = 0.0058) but similar device and procedure-specific risk factors (P = 0.17). Cardiac implantable electronic device infection occurred in 0/654 (0%) of the TauroPace group and 6/551 (1.1%) of the H2O2 group (P = 0.0075). Death occurred in 23/654 (3.5%) of the TauroPace group and 14/551 (2.5%) of the H2O2 group (P = 0.33). Non-infection related adverse events were rarer in the TauroPace (3.8%) than the H2O2 (6.0%) group (P = 0.0802). TauroPace is safe but more effective than H2O2 in reducing CIED infection. ClinicalTrials.gov Identifier: NCT05576194

1 May 2000 in Pacing and Clinical Electrophysiology
Verified
Journal Article
Closed access
PDF file
UWUwe K.H. Wiegand
Uwe K.H. Wiegand
JPJürgen Potratz
Jürgen Potratz
FBFrank Bode
Frank Bode
RSRegina Schneider
Regina Schneider
WPWerner Peters
Werner Peters
HKHugo Katus
Hugo Katus

12 November 2025 in Advanced Healthcare Materials
Verified
Journal Article
Open access
BBBenito Baldauf
Benito Baldauf
HBHendrik Bonnemeier
Hendrik Bonnemeier
ELErnest W. Lau
Ernest W. Lau
JHJana Hummel
Jana Hummel
RVReinhard Vonthein
Reinhard Vonthein
OAOjan Assadian
Ojan Assadian
Implantable medical devices, including cardiac electronic implants, joint prostheses, and breast implants, are essential to modern healthcare but remain susceptible to infection from microbial contamination during placement. Staphylococcus spp . and Candida albicans are the predominant pathogens, often causing severe complications, increased mortality, and substantial healthcare costs. With antibiotic resistance on the rise, intraoperative surface disinfection has emerged as a critical yet underutilized preventive strategy. Taurolidine, a broad‐spectrum antimicrobial with a strong safety profile and no known resistance, can be applied directly to both tissues and device surfaces. To replicate intraoperative decontamination, taurolidine‐saturated swabs are tested under standardized mechanical wiping using the European Norm EN 16615 “4‐field test.” The model reproduced short contact times and organic load conditions reflective of clinical practice, enabling assessment of both chemical and mechanical antimicrobial effects. Taurolidine achieved >5 log 10 reductions in Staphylococcus aureus , Pseudomonas aeruginosa , and Candida albicans , and >4 log 10 for Enterococcus hirae . The observed activity demonstrated a surface‐driven, enzyme‐independent mechanism involving spontaneous release of reactive N‐methylol functional groups that disrupt microbial membranes. Taurolidine's enzyme‐independent antimicrobial mechanism distinguishes it from solvent‐ or oxidant‐based disinfectants. These results support taurolidine as a potential adjunctive prophylactic agent to reduce device‐related infections during implantation procedures.

1 May 2006 in Heart Rhythm
Verified
Journal Article
Closed access
PDF file
FEFrank Eberhardt
Frank Eberhardt
THThorsten Hanke
Thorsten Hanke
MBMathias Bechtel
Mathias Bechtel
HBHendrik Bonnemeier
Hendrik Bonnemeier
UWUwe K.H. Wiegand
Uwe K.H. Wiegand
MMMartin Misfeld
Martin Misfeld